SK14152003A3 - Pediatrický prípravok gatifloxacínu - Google Patents

Pediatrický prípravok gatifloxacínu Download PDF

Info

Publication number: SK14152003A3
Authority: SK; Slovakia
Prior art keywords: precipitate; crystalline; gatifloxacin; fatty acid; acid
Prior art date: 2001-06-20

Application number

SK1415-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Krishnaswamy S. Raghavan

Sunanda A Ranadive

Kenneth S. Bembenek

Loutfy Benkerrour

Veronique Trognon

Richard G. Corrao

Luigi Esposito

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-20

Filing date

2002-05-10

Publication date

2004-06-08

2002-05-10 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-06-08 Publication of SK14152003A3 publication Critical patent/SK14152003A3/sk

Links

XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 title claims abstract description 65
229960003923 gatifloxacin Drugs 0.000 title claims abstract description 65
239000000203 mixture Substances 0.000 title claims abstract description 35
238000009472 formulation Methods 0.000 title abstract description 14
239000002244 precipitate Substances 0.000 claims abstract description 61
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 32
239000008117 stearic acid Substances 0.000 claims abstract description 26
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 25
235000021355 Stearic acid Nutrition 0.000 claims abstract description 24
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 24
235000021314 Palmitic acid Nutrition 0.000 claims abstract description 16
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 16
239000007900 aqueous suspension Substances 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims description 30
235000014113 dietary fatty acids Nutrition 0.000 claims description 27
239000000194 fatty acid Substances 0.000 claims description 27
229930195729 fatty acid Natural products 0.000 claims description 27
150000004665 fatty acids Chemical class 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 14
238000001816 cooling Methods 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
238000004090 dissolution Methods 0.000 claims description 8
238000010992 reflux Methods 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
235000003599 food sweetener Nutrition 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 7
239000003765 sweetening agent Substances 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 6
238000010438 heat treatment Methods 0.000 claims description 6
239000004615 ingredient Substances 0.000 claims description 6
239000002002 slurry Substances 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 3
RMJMZKDEVNTXHE-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 RMJMZKDEVNTXHE-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 6
239000000546 pharmaceutical excipient Substances 0.000 claims 1
235000019640 taste Nutrition 0.000 abstract description 27
235000019658 bitter taste Nutrition 0.000 abstract description 12
238000010521 absorption reaction Methods 0.000 abstract description 3
229940072132 quinolone antibacterials Drugs 0.000 abstract description 3
210000002784 stomach Anatomy 0.000 abstract description 3
239000003814 drug Substances 0.000 description 19
239000000725 suspension Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 12
239000002245 particle Substances 0.000 description 11
229940124597 therapeutic agent Drugs 0.000 description 11
238000002425 crystallisation Methods 0.000 description 8
230000008025 crystallization Effects 0.000 description 8
239000000796 flavoring agent Substances 0.000 description 8
230000000873 masking effect Effects 0.000 description 8
239000008187 granular material Substances 0.000 description 7
239000000126 substance Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 4
239000008135 aqueous vehicle Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
235000019634 flavors Nutrition 0.000 description 4
235000013355 food flavoring agent Nutrition 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000011161 development Methods 0.000 description 3
XUBOMFCQGDBHNK-UHFFFAOYSA-N gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 XUBOMFCQGDBHNK-UHFFFAOYSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011343 solid material Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
108010011485 Aspartame Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000605 aspartame Substances 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
229960003438 aspartame Drugs 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
229940100692 oral suspension Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
-1 quinolone compound Chemical class 0.000 description 2
238000010583 slow cooling Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006068 taste-masking agent Substances 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
206010019670 Hepatic function abnormal Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
235000000556 Paullinia cupana Nutrition 0.000 description 1
240000003444 Paullinia cupana Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940126573 antibacterial therapeutic Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
238000012769 bulk production Methods 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
229960002620 cefuroxime axetil Drugs 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Seasonings (AREA)

SK1415-2003A 2001-06-20 2002-05-10 Pediatrický prípravok gatifloxacínu SK14152003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29962501P	2001-06-20	2001-06-20
PCT/US2002/014596 WO2003000175A2 (en)	2001-06-20	2002-05-10	Pediatric formulation of gatifloxacin

Publications (1)

Publication Number	Publication Date
SK14152003A3 true SK14152003A3 (sk)	2004-06-08

Family

ID=23155586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1415-2003A SK14152003A3 (sk)	2001-06-20	2002-05-10	Pediatrický prípravok gatifloxacínu

Country Status (29)

Country	Link
US (1)	US6589955B2 (pl)
EP (1)	EP1406572A4 (pl)
JP (1)	JP4617475B2 (pl)
KR (1)	KR100888519B1 (pl)
CN (1)	CN1264514C (pl)
AR (1)	AR034483A1 (pl)
AU (1)	AU2002345534B2 (pl)
BG (1)	BG108444A (pl)
BR (1)	BR0209692A (pl)
CA (1)	CA2450742A1 (pl)
CZ (1)	CZ20033487A3 (pl)
EE (1)	EE200400018A (pl)
GE (1)	GEP20053610B (pl)
HR (1)	HRP20031027A2 (pl)
HU (1)	HUP0401497A2 (pl)
IL (1)	IL158863A0 (pl)
IS (1)	IS7048A (pl)
MX (1)	MXPA03011451A (pl)
NO (1)	NO20035605D0 (pl)
NZ (1)	NZ529611A (pl)
PE (1)	PE20030126A1 (pl)
PL (1)	PL366559A1 (pl)
RU (1)	RU2288218C2 (pl)
SK (1)	SK14152003A3 (pl)
TW (1)	TWI224004B (pl)
UA (1)	UA75656C2 (pl)
WO (1)	WO2003000175A2 (pl)
YU (1)	YU100303A (pl)
ZA (1)	ZA200309173B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8383154B2 (en)	2004-05-11	2013-02-26	Egalet A/S	Swellable dosage form comprising gellan gum
US7838532B2 (en) *	2005-05-18	2010-11-23	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) *	2005-05-18	2013-10-01	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
US20070051418A1 (en) *	2005-09-02	2007-03-08	Rowles Brian A	Multilayer tubes
TW201010708A (en) *	2008-06-02	2010-03-16	Intervet Int Bv	Composition comprising an antibiotic and a corticosteroid
CN102325532B (zh) *	2008-10-07	2015-06-17	Mpex医药有限公司	用于减轻肺部炎症的左氧氟沙星吸入剂
AU2009302478B2 (en) *	2008-10-07	2015-09-03	Horizon Orphan Llc	Aerosol fluoroquinolone formulations for improved pharmacokinetics
LT2473170T (lt)	2009-09-04	2019-10-10	Horizon Orphan Llc	Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
CN102397546A (zh) *	2010-09-10	2012-04-04	广州自远生物科技有限公司	一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) *	2010-09-10	2016-06-08	广州自远生物科技有限公司	一种含喹诺酮类的药物复合制剂及其制备方法和应用
WO2014152332A1 (en)	2013-03-15	2014-09-25	Melinta Therapeutics, Inc.	Methods of treating infections in overweight and obese patients using antibiotics
WO2018129079A1 (en) *	2017-01-03	2018-07-12	Thermolife International, Llc	Method of isolating theacrine and composition comprising theacrine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO88836A2 (ro)	1983-10-11	1986-03-31	Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro	Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric
JPH089597B2 (ja)	1986-01-21	1996-01-31	杏林製薬株式会社	選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
NL193682C (nl)	1987-05-14	2000-07-04	Glaxo Group Ltd	Beklede cefuroximaxetilsamenstelling.
US5405617A (en)	1991-11-07	1995-04-11	Mcneil-Ppc, Inc.	Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
IT1255792B (it)	1992-08-05	1995-11-16	Bayer Italia Spa	Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5407921A (en)	1993-07-01	1995-04-18	Kao Corporation	Method for suppressing bitter taste
JP3449658B2 (ja)	1994-12-21	2003-09-22	杏林製薬株式会社	安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
DE19633480A1 (de)	1996-08-20	1998-02-26	Bayer Ag	Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US5891469A (en)	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2227314A1 (en)	1997-01-24	1998-07-24	Hoechst Aktiengesellschaft	Preparation of concealed taste preparations of antibacterially active quinolone derivatives
GB9702799D0 (en)	1997-02-12	1997-04-02	Scherer Corp R P	Process for preparing solid pharmaceutical dosage forms
DE19820801A1 (de) *	1998-05-09	1999-11-25	Gruenenthal Gmbh	Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DK1200129T3 (da)	1999-07-14	2009-01-12	Schering Plough Ltd	Smagsmaskering af orale, flydende quinolonfremstillinger ved anvendelse af ionbytterharpikser

2002
- 2002-05-09 US US10/143,487 patent/US6589955B2/en not_active Expired - Lifetime
- 2002-05-10 EE EEP200400018A patent/EE200400018A/xx unknown
- 2002-05-10 JP JP2003506621A patent/JP4617475B2/ja not_active Expired - Fee Related
- 2002-05-10 MX MXPA03011451A patent/MXPA03011451A/es active IP Right Grant
- 2002-05-10 CA CA002450742A patent/CA2450742A1/en not_active Abandoned
- 2002-05-10 PL PL02366559A patent/PL366559A1/pl not_active Application Discontinuation
- 2002-05-10 WO PCT/US2002/014596 patent/WO2003000175A2/en not_active Ceased
- 2002-05-10 AU AU2002345534A patent/AU2002345534B2/en not_active Ceased
- 2002-05-10 EP EP02744141A patent/EP1406572A4/en not_active Withdrawn
- 2002-05-10 CZ CZ20033487A patent/CZ20033487A3/cs unknown
- 2002-05-10 CN CNB02812409XA patent/CN1264514C/zh not_active Expired - Fee Related
- 2002-05-10 RU RU2003136068/04A patent/RU2288218C2/ru not_active IP Right Cessation
- 2002-05-10 YU YU100303A patent/YU100303A/sh unknown
- 2002-05-10 BR BR0209692-7A patent/BR0209692A/pt not_active IP Right Cessation
- 2002-05-10 HR HR20031027A patent/HRP20031027A2/hr not_active Application Discontinuation
- 2002-05-10 NZ NZ529611A patent/NZ529611A/en unknown
- 2002-05-10 GE GE5383A patent/GEP20053610B/en unknown
- 2002-05-10 SK SK1415-2003A patent/SK14152003A3/sk unknown
- 2002-05-10 HU HU0401497A patent/HUP0401497A2/hu unknown
- 2002-05-10 KR KR1020037016647A patent/KR100888519B1/ko not_active Expired - Fee Related
- 2002-05-10 IL IL15886302A patent/IL158863A0/xx unknown
- 2002-06-13 AR ARP020102227A patent/AR034483A1/es not_active Application Discontinuation
- 2002-06-14 TW TW091113074A patent/TWI224004B/zh not_active IP Right Cessation
- 2002-06-18 PE PE2002000518A patent/PE20030126A1/es not_active Application Discontinuation
- 2002-10-05 UA UA20031211971A patent/UA75656C2/uk unknown
2003
- 2003-11-20 IS IS7048A patent/IS7048A/is unknown
- 2003-11-25 ZA ZA200309173A patent/ZA200309173B/en unknown
- 2003-12-12 BG BG108444A patent/BG108444A/xx unknown
- 2003-12-16 NO NO20035605A patent/NO20035605D0/no unknown

Also Published As

Publication number	Publication date
EP1406572A4 (en)	2005-05-25
PL366559A1 (pl)	2005-02-07
UA75656C2 (en)	2006-05-15
CZ20033487A3 (cs)	2004-05-12
HRP20031027A2 (en)	2005-10-31
EP1406572A2 (en)	2004-04-14
IS7048A (is)	2003-11-20
KR20040011543A (ko)	2004-02-05
PE20030126A1 (es)	2003-02-08
HUP0401497A2 (hu)	2004-12-28
BG108444A (en)	2004-08-31
CN1264514C (zh)	2006-07-19
EE200400018A (et)	2004-04-15
MXPA03011451A (es)	2004-04-05
WO2003000175A3 (en)	2003-04-10
AR034483A1 (es)	2004-02-25
IL158863A0 (en)	2004-05-12
RU2003136068A (ru)	2005-02-10
GEP20053610B (en)	2005-09-12
JP2005500306A (ja)	2005-01-06
US6589955B2 (en)	2003-07-08
WO2003000175A2 (en)	2003-01-03
BR0209692A (pt)	2004-04-20
NO20035605D0 (no)	2003-12-16
TWI224004B (en)	2004-11-21
JP4617475B2 (ja)	2011-01-26
ZA200309173B (en)	2005-02-25
YU100303A (sh)	2006-08-17
KR100888519B1 (ko)	2009-03-11
US20030028025A1 (en)	2003-02-06
NZ529611A (en)	2006-02-24
CN1518449A (zh)	2004-08-04
CA2450742A1 (en)	2003-01-03
AU2002345534B2 (en)	2007-07-12
RU2288218C2 (ru)	2006-11-27

Legal Events

Date	Code	Title	Description
2010-08-09	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
EP0293885B1 (en)	1993-09-29	Antibiotic-polymer compositions
AU2008320458B2 (en)	2014-01-23	Stabilized pediatric suspension of carisbamate
US20050136114A1 (en)	2005-06-23	Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
EP1446126A1 (en)	2004-08-18	Coated particulate cefuroxime axetil compositions
US5460829A (en)	1995-10-24	Pharmaceutical compositions based on ebastine or analogues thereof
US6589955B2 (en)	2003-07-08	Pediatric formulation of gatifloxacin
AU2002345534A1 (en)	2003-06-19	Pediatric formulation of gatifloxacin
EP2538923A2 (en)	2013-01-02	Taste-masked powder for suspension compositions of methylprednisolone
EP4642439A1 (en)	2025-11-05	A stable ready to use suspension of stiripentol
US6515008B1 (en)	2003-02-04	Formulation
KR20250041170A (ko)	2025-03-25	항경련제의 안정한 약제학적 경구용 액체 제형
PL192361B1 (pl)	2006-10-31	Kompozycja farmaceutyczna hemihydratu newirapiny i sposób wytwarzania wodnej zawiesiny hemihydratu newirapiny
EP2558079B1 (en)	2019-05-22	Ciprofloxacin dry syrup composition
GB2586201A (en)	2021-02-17	A stable powder formulation of racecadotril
CZ20014133A3 (cs)	2002-03-13	Farmaceutický přípravek a způsob jeho přípravy
WO2025144113A1 (en)	2025-07-03	Pharmaceutical composition of chenodeoxycholic acid for pediatric use